HBM4003 is a recombinant, fully humanized, monoclonal, heavy chain only anti-CTLA-4 antibody against cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) developed through our proprietary HCAb technology. The CTLA-4 pathway is a key immune checkpoint pathway that provides a downregulating signal to T cells. HBM4003 specifically binds to CTLA-4 and inhibits the CTLA-4 axis. In addition, HBM4003 is engineered to significantly enhance ADCC and increase Treg cell depletion.
The focus of HBM4003 development is treatment of solid tumors with high unmet medical needs, for instance, patients intolerant to current immune oncology combination therapies that are associated with high toxicities.
Advantages of HBM4003
HBM4003 is engineered in its Fc region, increasing its potential to deplete intratumoral Treg. Via Treg depletion, HBM4003 has the increased potential to induce T cell activation, which is a critical step in generating potent immune responses against cancer. In addition, in preclinical studies, HBM4003 shows a promising safety profile which may result from the reduced drug exposure.
Mechanism of Action
HBM4003 stimulates the immune system by 2 mechanisms: inhibition of negative signaling from the interaction of CTLA-4 with the co-stimulatory molecule B7; and depletion of immune suppressive Treg through enhanced ADCC.
Currently Active Clinical Trials
Phase 1 Trial
HBM4003 is in a Phase 1 clinical trial in Australia. This is an open-label, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of HBM4003 in patients with advanced solid tumors that have progressed after all standard therapies.
We have the right to develop and commercialize HBM4003 globally and in Greater China.